VANDA PHARMACEUTICALS INC. Selling, General and Administrative Expense
VANDA PHARMACEUTICALS INC. (VNDA) reported Selling, General and Administrative Expense of $71.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $71.84M, a 11.18% increase year-over-year.
- VANDA PHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $68.36M, a 36.49% increase year-over-year.
- VANDA PHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $62.98M, a 60.32% increase year-over-year.
- VANDA PHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $60.27M, a 60.42% increase year-over-year.
- VANDA PHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2025 was $237.95M, a 62.52% increase from fiscal 2024.
- VANDA PHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2024 was $146.41M, a 29.70% increase from fiscal 2023.
- VANDA PHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2023 was $112.88M, a 17.29% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2022 was $136.49M, a 10.03% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $71.84M 10-Q · filed 2026-08-06 | $140.20M 10-Q · filed 2026-08-06 | $203.18M derived: sum of 3 quarters · filed 2026-08-06 | $263.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $68.36M 10-Q · filed 2026-05-07 | $131.34M derived: sum of 2 quarters · filed 2026-05-07 | $191.61M derived: sum of 3 quarters · filed 2026-05-07 | $256.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $62.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $123.25M derived: sum of 2 quarters · filed 2026-02-12 | $187.87M derived: sum of 3 quarters · filed 2026-08-06 | $237.95M 10-K · filed 2026-02-12 |
| 2025-09-30 | $60.27M 10-Q · filed 2025-10-30 | $124.89M derived: sum of 2 quarters · filed 2026-08-06 | $174.97M 10-Q · filed 2025-10-30 | $214.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $64.62M 10-Q · filed 2026-08-06 | $114.70M 10-Q · filed 2026-08-06 | $153.98M derived: sum of 3 quarters · filed 2026-08-06 | $191.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $50.08M 10-Q · filed 2026-05-07 | $89.37M derived: sum of 2 quarters · filed 2026-05-07 | $126.94M derived: sum of 3 quarters · filed 2026-05-07 | $166.41M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $39.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $76.86M derived: sum of 2 quarters · filed 2026-02-12 | $116.33M derived: sum of 3 quarters · filed 2026-02-12 | $146.41M 10-K · filed 2026-02-12 |
| 2024-09-30 | $37.57M 10-Q · filed 2025-10-30 | $77.05M derived: sum of 2 quarters · filed 2025-10-30 | $107.13M 10-Q · filed 2025-10-30 | $130.75M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $39.47M 10-Q · filed 2025-07-31 | $69.56M 10-Q · filed 2025-07-31 | $93.17M derived: sum of 3 quarters · filed 2026-02-12 | $117.94M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $30.09M 10-Q · filed 2025-05-08 | $53.70M derived: sum of 2 quarters · filed 2026-02-12 | $78.47M derived: sum of 3 quarters · filed 2026-02-12 | $106.86M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $23.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $48.38M derived: sum of 2 quarters · filed 2026-02-12 | $76.78M derived: sum of 3 quarters · filed 2026-02-12 | $112.88M 10-K · filed 2026-02-12 |
| 2023-09-30 | $24.77M 10-Q · filed 2024-11-07 | $53.17M derived: sum of 2 quarters · filed 2024-11-07 | $89.27M 10-Q · filed 2024-11-07 | $122.05M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $28.40M 10-Q · filed 2024-08-01 | $64.50M 10-Q · filed 2024-08-01 | $97.28M derived: sum of 3 quarters · filed 2025-02-14 | $127.14M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $36.10M 10-Q · filed 2024-05-09 | $68.89M derived: sum of 2 quarters · filed 2025-02-14 | $98.74M derived: sum of 3 quarters · filed 2025-02-14 | $131.74M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $32.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $62.64M derived: sum of 2 quarters · filed 2025-02-14 | $95.64M derived: sum of 3 quarters · filed 2025-02-14 | $136.49M 10-K · filed 2025-02-14 |
| 2022-09-30 | $29.85M 10-Q · filed 2023-11-09 | $62.85M derived: sum of 2 quarters · filed 2023-11-09 | $103.70M 10-Q · filed 2023-11-09 | $137.15M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-06-30 | $33.00M 10-Q · filed 2023-07-28 | $73.85M 10-Q · filed 2023-07-28 | $107.30M derived: sum of 3 quarters · filed 2024-02-08 | $139.75M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-03-31 | $40.85M 10-Q · filed 2023-05-03 | $74.30M derived: sum of 2 quarters · filed 2024-02-08 | $106.75M derived: sum of 3 quarters · filed 2024-02-08 | $135.10M derived: sum of 4 quarters · filed 2024-02-08 |
| 2021-12-31 | $33.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $65.90M derived: sum of 2 quarters · filed 2024-02-08 | $94.25M derived: sum of 3 quarters · filed 2024-02-08 | $124.05M 10-K · filed 2024-02-08 |
| 2021-09-30 | $32.46M 10-Q · filed 2022-11-03 | $60.80M derived: sum of 2 quarters · filed 2022-11-03 | $90.60M 10-Q · filed 2022-11-03 | $126.17M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $28.35M 10-Q · filed 2022-08-04 | $58.14M 10-Q · filed 2022-08-04 | $93.72M derived: sum of 3 quarters · filed 2023-02-09 | $127.72M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $29.80M 10-Q · filed 2022-05-06 | $65.37M derived: sum of 2 quarters · filed 2023-02-09 | $99.37M derived: sum of 3 quarters · filed 2023-02-09 | $133.29M derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $35.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $69.57M derived: sum of 2 quarters · filed 2023-02-09 | $103.49M derived: sum of 3 quarters · filed 2023-02-09 | $140.51M 10-K · filed 2023-02-09 |
| 2020-09-30 | $34.00M 10-Q · filed 2021-11-04 | $67.92M derived: sum of 2 quarters · filed 2021-11-04 | $104.94M 10-Q · filed 2021-11-04 | $141.96M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $33.92M 10-Q · filed 2021-07-29 | $70.94M 10-Q · filed 2021-07-29 | $107.96M derived: sum of 3 quarters · filed 2022-02-24 | $138.18M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $37.02M 10-Q · filed 2021-05-06 | $74.04M derived: sum of 2 quarters · filed 2022-02-24 | $104.26M derived: sum of 3 quarters · filed 2022-02-24 | $135.73M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $37.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $67.24M derived: sum of 2 quarters · filed 2022-02-24 | $98.71M derived: sum of 3 quarters · filed 2022-02-24 | $129.74M 10-K · filed 2022-02-24 |
| 2019-09-30 | $30.22M 10-Q · filed 2020-10-29 | $61.69M derived: sum of 2 quarters · filed 2020-10-29 | $92.72M 10-Q · filed 2020-10-29 | $117.64M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $31.47M 10-Q · filed 2020-08-06 | $62.50M 10-Q · filed 2020-08-06 | $87.42M derived: sum of 3 quarters · filed 2021-02-11 | $113.47M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $31.03M 10-Q · filed 2020-05-07 | $55.95M derived: sum of 2 quarters · filed 2021-02-11 | $82.00M derived: sum of 3 quarters · filed 2021-02-11 | $109.96M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $24.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $50.97M derived: sum of 2 quarters · filed 2021-02-11 | $78.93M derived: sum of 3 quarters · filed 2021-02-11 | $105.75M 10-K · filed 2021-02-11 |
| 2018-09-30 | $26.05M 10-Q · filed 2019-11-07 | $54.01M derived: sum of 2 quarters · filed 2019-11-07 | $80.83M 10-Q · filed 2019-11-07 | $111.88M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $27.96M 10-Q · filed 2019-08-01 | $54.78M 10-Q · filed 2019-08-01 | $85.83M derived: sum of 3 quarters · filed 2020-02-26 | $116.95M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $26.82M 10-Q · filed 2019-05-03 | $57.87M derived: sum of 2 quarters · filed 2020-02-26 | $89.00M derived: sum of 3 quarters · filed 2020-02-26 | $120.37M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $31.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $62.17M derived: sum of 2 quarters · filed 2020-02-26 | $93.54M derived: sum of 3 quarters · filed 2020-02-26 | $123.84M 10-K · filed 2020-02-26 |
| 2017-09-30 | $31.12M 10-Q · filed 2018-11-07 | $62.49M derived: sum of 2 quarters · filed 2018-11-07 | $92.79M 10-Q · filed 2018-11-07 | $116.70M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-06-30 | $31.37M 10-Q · filed 2018-08-02 | $61.67M 10-Q · filed 2018-08-02 | $85.58M derived: sum of 3 quarters · filed 2019-02-19 | $107.48M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-03-31 | $30.30M 10-Q · filed 2018-05-02 | $54.20M derived: sum of 2 quarters · filed 2019-02-19 | $76.11M derived: sum of 3 quarters · filed 2019-02-19 | $100.79M derived: sum of 4 quarters · filed 2019-02-19 |
| 2016-12-31 | $23.91M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $45.81M derived: sum of 2 quarters · filed 2019-02-19 | $70.50M derived: sum of 3 quarters · filed 2019-02-19 | $99.79M 10-K · filed 2019-02-19 |
| 2016-09-30 | $21.91M 10-Q · filed 2017-11-08 | $46.59M derived: sum of 2 quarters · filed 2017-11-08 | $75.88M 10-Q · filed 2017-11-08 | $104.76M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $24.68M 10-Q · filed 2017-08-03 | $53.97M 10-Q · filed 2017-08-03 | $82.85M derived: sum of 3 quarters · filed 2018-02-15 | $101.31M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $29.29M 10-Q · filed 2017-05-03 | $58.17M derived: sum of 2 quarters · filed 2018-02-15 | $76.63M derived: sum of 3 quarters · filed 2018-02-15 | $95.02M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $28.88M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $47.34M derived: sum of 2 quarters · filed 2018-02-15 | $65.72M derived: sum of 3 quarters · filed 2018-02-15 | $84.53M 10-K · filed 2018-02-15 |
| 2015-09-30 | $18.46M 10-Q · filed 2016-11-03 | $36.84M derived: sum of 2 quarters · filed 2016-11-03 | $55.65M 10-Q · filed 2016-11-03 | $72.97M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $18.39M 10-Q · filed 2016-07-28 | $37.19M 10-Q · filed 2016-07-28 | $54.52M derived: sum of 3 quarters · filed 2017-02-17 | $65.81M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $18.81M 10-Q · filed 2016-05-05 | $36.13M derived: sum of 2 quarters · filed 2017-02-17 | $47.42M derived: sum of 3 quarters · filed 2017-02-17 | $75.56M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $17.32M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $28.61M derived: sum of 2 quarters · filed 2017-02-17 | $56.75M derived: sum of 3 quarters · filed 2017-02-17 | $84.64M 10-K · filed 2017-02-17 |
| 2014-09-30 | $11.29M 10-Q · filed 2015-11-04 | $39.43M derived: sum of 2 quarters · filed 2015-11-04 | $67.32M 10-Q · filed 2015-11-04 | $77.25M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $28.14M 10-Q · filed 2015-07-31 | $56.03M 10-Q · filed 2015-07-31 | $65.96M derived: sum of 3 quarters · filed 2016-02-12 | $71.70M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $27.89M 10-Q · filed 2015-05-07 | $37.82M derived: sum of 2 quarters · filed 2016-02-12 | $43.56M derived: sum of 3 quarters · filed 2016-02-12 | $48.82M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $9.93M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $15.67M derived: sum of 2 quarters · filed 2016-02-12 | $20.93M derived: sum of 3 quarters · filed 2016-02-12 | $25.08M 10-K · filed 2016-02-12 |
| 2013-09-30 | $5.74M 10-Q · filed 2014-10-27 | $11.00M derived: sum of 2 quarters · filed 2014-10-27 | $15.15M 10-Q · filed 2014-10-27 | |
| 2013-06-30 | $5.26M 10-Q · filed 2014-08-08 | $9.41M 10-Q · filed 2014-08-08 | ||
| 2013-03-31 | $4.15M 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | $14.52M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |